FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 326:1055-1058 April 16, 1992 Number 16 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Allogeneic bone marrow transplantation is an accepted therapy for hematologic cancer, aplastic anemia, and inherited immunodeficiencies. Chronic graft-versus-host disease (GVHD) is the principal complication in patients surviving more than 100 days. Thalidomide has been shown experimentally to be effective in treating GVHD. METHODS. We treated 23 patients with chronic GVHD refractory to conventional treatment and 21 patients with "high-risk" chronic GVHD (identified as having at least two of the following three risk factors: chronic GVHD that has evolved from acute GVHD, lichenoid skin or mucous-membrane changes, and hepatic dysfunction. Such patients have a high mortality rate.) with thalidomide in a dose that produced a plasma level of 5 micrograms per milliliter two hours after administration. Therapy was continued for three months after a complete response or for six months after a partial response. RESULTS. The overall actuarial survival of all enrolled patients was 64 percent. Survival was 76 percent among the patients receiving salvage therapy for refractory GVHD and 48 percent among those with high-risk GVHD. A complete response was observed in 14 patients, a partial response in 12 patients, and no response in 18. Side effects were minor, most notably sedation in almost all patients. CONCLUSIONS. In this preliminary trial, thalidomide appeared to be safe and effective for the treatment of chronic GVHD. A trial comparing thalidomide with prednisone in patients with newly diagnosed chronic GVHD will be required to demonstrate its relative efficacy.

Source Information

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Md.

This article has been cited by other articles:

• Okada, Y., Murayama, N., Yanagida, C., Shimizu, M., Guengerich, F. P., Yamazaki, H. (2009). Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5. Drug Metab. Dispos. 37: 18-23 [Abstract] [Full Text]  
• Lee, C. P., Patel, P. M., Selby, P. J., Hancock, B. W., Mak, I., Pyle, L., James, M. G., Beirne, D. A., Steeds, S., A'Hern, R., Gore, M. E., Eisen, T. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 898-903 [Abstract] [Full Text]  
• LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., Anderson, K. C., Munshi, N. C. (2004). Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103: 1787-1790 [Abstract] [Full Text]  
• Gee, M. S., Makonnen, S., al-Kofahi, K., Roysam, B., Payvandi, F., Man, H.-W., Muller, G. W., Lee, W. M. F. (2003). Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition. Cancer Res. 63: 8073-8078 [Abstract] [Full Text]  
• Nasca, M. R, Micali, G., Cheigh, N. H, West, L. E, West, D. P (2003). Dermatologic and Nondermatologic Uses of Thalidomide. The Annals of Pharmacotherapy 37: 1307-1320 [Abstract] [Full Text]  
• Gordon, J N, Goggin, P M (2003). Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J. 79: 127-132 [Abstract] [Full Text]  
• Chaudhry, V., Cornblath, D. R., Corse, A., Freimer, M., Simmons-O'Brien, E., Vogelsang, G. (2002). Thalidomide-induced neuropathy. Neurology 59: 1872-1875 [Abstract] [Full Text]  
• Mohty, M., Stoppa, A.-M., Blaise, D., Isnardon, D., Gastaut, J.-A., Olive, D., Gaugler, B. (2002). Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J. Leukoc. Biol. 72: 939-945 [Abstract] [Full Text]  
• Eisen, T. (2002). Thalidomide in Solid Malignancies. JCO 20: 2607-2609 [Full Text]  
• Majumdar, S., Lamothe, B., Aggarwal, B. B. (2002). Thalidomide Suppresses NF-{kappa}B Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester. J. Immunol. 168: 2644-2651 [Abstract] [Full Text]  
• Bauditz, J, Wedel, S, Lochs, H (2002). Thalidomide reduces tumour necrosis factor {alpha} and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200 [Abstract] [Full Text]  
• Maloney, D. G., Sandmaier, B. M., Mackinnon, S., Shizuru, J. A. (2002). Non-Myeloablative Transplantation. ASH Education Book 2002: 392-421 [Abstract] [Full Text]  
• Wingard, J. R., Vogelsang, G. B., Deeg, H. J. (2002). Stem Cell Transplantation: Supportive Care and Long-Term Complications. ASH Education Book 2002: 422-444 [Abstract] [Full Text]  
• Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I., Anderson, K. C. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216 [Abstract] [Full Text]  
• Karim, M Y, Ruiz-Irastorza, G, Khamashta, M A, Hughes, G R. (2001). Update on therapy -- thalidomide in the treatment of lupus. Lupus 10: 188-192 [Abstract]  
• Vogelsang, G. B. (2001). How I treat chronic graft-versus-host disease. Blood 97: 1196-1201 [Abstract] [Full Text]  
• Teo, S. K., Evans, M. G., Brockman, M. J., Ehrhart, J., Morgan, J. M., Stirling, D. I., Thomas, S. D. (2001). Safety Profile of Thalidomide after 53 Weeks of Oral Administration in Beagle Dogs. Toxicol Sci 59: 160-168 [Abstract] [Full Text]  
• Koc, S., Leisenring, W., Flowers, M. E. D., Anasetti, C., Deeg, H. J., Nash, R. A., Sanders, J. E., Witherspoon, R. P., Appelbaum, F. R., Storb, R., Martin, P. J. (2000). Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 96: 3995-3996 [Abstract] [Full Text]  
• Teo, S, Evans, M, Ehrhart, J, Brockman, M, Allen, D, Morgan, M, Stirling, D, Thomas, S (2000). Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules. Hum Exp Toxicol 19: 615-622 [Abstract]  
• Kapelushnik, J., Weiss, L., Pappo, O., Okon, E., Or, R. (1999). Thalidomide does not interfere with graft-versus-leukemia reactivity in mice. J Oncol Pharm Pract 5: 179-183 [Abstract]  
• Ridoux, O., Drancourt, M. (1999). Lack of In Vitro Antimicrosporidian Activity of Thalidomide. Antimicrob. Agents Chemother. 43: 2305-2306 [Abstract] [Full Text]  
• Teo, S. K., Trigg, N. J., Shaw, M. E., Morgan, J. M., Thomas, S. D. (1999). Subchronic Toxicity of Thalidomide in Rodents After 13 Weeks of Oral Administration. International Journal of Toxicology 18: 337-352 [Abstract]  
• Duong, D. J., Spigel, G. T., Moxley III, R. T., Gaspari, A. A. (1999). American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus. Arch Dermatol 135: 1079-1087 [Abstract] [Full Text]  
• Mehta, P., Kedar, A., Graham-Pole, J., Skoda-Smith, S., Wingard, J. R. (1999). Thalidomide in Children Undergoing Bone Marrow Transplantation: Series at a Single Institution and Review of the Literature. Pediatrics 103: 44e-44 [Abstract] [Full Text]  
• Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M. G., Stirling, D., Dalgleish, A. G. (1998). CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-{alpha} Production. J. Immunol. 161: 4236-4243 [Abstract] [Full Text]  
• Haslett, P. A.J., Corral, L. G., Albert, M., Kaplan, G. (1998). Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset. JEM 187: 1885-1892 [Abstract] [Full Text]  
• Aractingi, S., Chosidow, O. (1998). Cutaneous Graft-versus-Host Disease. Arch Dermatol 134: 602-612 [Abstract] [Full Text]  
• Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., Vasquez, G. J., Wohl, D. A., The National Institute of Allergy and Infectious D, (1997). Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection. NEJM 336: 1487-1493 [Abstract] [Full Text]  
• Lee, S. J., Wegner, S. A., McGarigle, C. J., Bierer, B. E., Antin, J. H. (1997). Treatment of Chronic Graft-Versus-Host Disease With Clofazimine. Blood 89: 2298-2302 [Abstract] [Full Text]  
• Woo, S.-B., Lee, S. J., Schubert, M. M. (1997). Graft-vs.-Host Disease. CROBM 8: 201-216 [Abstract] [Full Text]  
• Powell, R J (1996). New roles for thalidomide. BMJ 313: 377-378 [Full Text]  
• Uthoff, K., Zehr, K. J., Gaudin, P. B., Kumar, P., Cho, P. W., Vogelsang, G., Hruban, R. H., Baumgartner, W. A., Stuart, R. S. (1995). Thalidomide as Replacement for Steroids in Immunosuppression After Lung Transplantation. Ann. Thorac. Surg. 59: 277-282 [Abstract] [Full Text]  
• Armitage, J. O. (1994). Bone Marrow Transplantation. NEJM 330: 827-838 [Full Text]  
• Coskuncan, N. M., Jabs, D. A., Dunn, J. P., Haller, J. A., Green, W. R., Vogelsang, G. B., Santos, G. W. (1994). The Eye in Bone Marrow Transplantation: VI. Retinal Complications. Arch Ophthalmol 112: 372-379 [Abstract]  
• Ochonisky, S., Verroust, J., Bastuji-Garin, S., Gherardi, R., Revuz, J. (1994). Thalidomide Neuropathy Incidence and Clinicoelectrophysiologic Findings in 42 Patients. Arch Dermatol 130: 66-69 [Abstract]  
• Holm, A. L., Bowers, K. E., McMeekin, T. O., Gaspari, A. A. (1993). Chronic Cutaneous Lupus Erythematosus Treated With Thalidomide. Arch Dermatol 129: 1548-1550 [Abstract]  
• Dunn, J. P., Jabs, D. A., Wingard, J., Enger, C., Vogelsang, G., Santos, G. (1993). Bone Marrow Transplantation and Cataract Development. Arch Ophthalmol 111: 1367-1373 [Abstract]